Related Experiment Video

Updated: Feb 19, 2026

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma
07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

7.2K

JAB1-STAT3 activation loop is associated with recurrence following 5-fluorouracil-based adjuvant chemotherapy in

Naruji Kugimiya1, Arata Nishimoto1, Tohru Hosoyama1

  • 1Department of Surgery and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan.

Oncology Letters
|November 9, 2017
PubMed

Insights

High expression of Jun activation domain-binding protein 1 (JAB1) predicts recurrence in colorectal cancer patients treated with 5-fluorouracil (5-FU) chemotherapy. Combined high JAB1 and STAT3 expression further lowers recurrence-free survival, suggesting JAB1 as a predictive marker.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Jun activation domain-binding protein 1 (JAB1) plays roles in tumorigenesis by degrading tumor suppressors and activating oncogenes.
  • A positive feedback loop exists between JAB1 and signal transducer and activator of transcription 3 (STAT3) in colon cancer cells.
  • High JAB1 expression correlates with poor prognosis in various cancers, but its role in colorectal cancer prognosis is unclear.

Purpose of the Study:

  • To investigate the association between JAB1 and STAT3 expression and recurrence in colorectal cancer.
  • To determine if JAB1 expression can predict recurrence in colorectal cancer patients undergoing 5-fluorouracil (5-FU)-based adjuvant chemotherapy.

Main Methods:

  • Analysis of JAB1 and STAT3 expression in primary colorectal cancer tissues.
  • Correlation of JAB1 and STAT3 expression levels with patient recurrence and survival rates after 5-FU-based chemotherapy.

Main Results:

  • High JAB1 expression in primary colorectal cancer tissues independently predicts recurrence after 5-FU-based adjuvant chemotherapy.
  • Co-expression of high JAB1 and STAT3 is associated with significantly lower recurrence-free survival compared to high expression of either marker alone.
  • The JAB1-STAT3 activation loop is implicated in colorectal cancer recurrence.

Conclusions:

  • JAB1 is a novel predictive marker for recurrence in colorectal cancer patients receiving 5-FU-based adjuvant chemotherapy.
  • The JAB1-STAT3 pathway represents a potential therapeutic target for recurrent colorectal cancer post-chemotherapy.
Keywords:
5-FU-based adjuvant chemotherapyJAB1JAB1-STAT3 activation loopSTAT3colorectal cancerrecurrence

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.5K
Quantification of Colonic Stem Cell Mutations07:53

Quantification of Colonic Stem Cell Mutations

Published on: September 25, 2015

7.1K

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.1K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
24